S6.14.3 – Louise and Roger React to Empowered SLD Patient Advocates
After the roundtable, Louise Campbell and Roger Green share their reactions to the enthusiastic, empowered advocates who are the Harrison Fellows.
October 9, 2025
After the roundtable, Louise Campbell and Roger Green share their reactions to the enthusiastic, empowered advocates who are the Harrison Fellows.
The co-hosts continue their look at major MASH stories from the first half of 2025 and two co-authors from a recent Lancet article on advanced liver screening join Roger Green to discuss their article.
Four leading Key Opinion Leaders join Roger Green to discuss the implications of semaglutide’s approval in the U.S. This conversation covers how the healthcare system will manage the tsunami of new patients resulting from increases in disease education and publicity.
Four leading Key Opinion Leaders join Roger Green to discuss the implications of semaglutide’s approval in the U.S. This conversation covers pharmacotherapy choices and the benefits this decision offers for patients.
Four leading US KOLs join Roger Green to discuss how the recent FDA approval of semaglutide in MASH will lead to dramatic changes in MASLD care in the US.
Dr. Emily Andaya joins Louise Campbell and Roger Green to discuss the American Heart Association’s CKM initiative and why she believes it should include “L” for liver.
Physicians Who Run Multi-Metabolic Clinics in the US and Spain Join Louise Campbell To Discuss Their Clinics (Part I)
This episode focuses on “multi-metabolic medicine,” including a roundtable whose guests run multi-metabolic practices in the US and Spain and an interview with Dr. Emily Andaya, an advocate for including the liver in the American Heart Associations’s CKM initiative.
On the first anniversary of Stephen Harrison’s passing, we take an episode to remember our co-founder and colleague, Stephen Harrison, his contributions to MASH and how his legacy moves forward.
SurfingMASH kicks off a month of Drug Development stories looking at FGF-21s and the future of therapies for cirrhosis and MASH, plus a paper on real-world resmetirom prescribing.